Lanreotide Acetate Research Grade Peptide (Somatostatin Analog) Supplier — UPOR Biotech
Lanreotide acetate is the acetate salt of lanreotide (BIM 23014), a synthetic cyclic octapeptide somatostatin-14 analogue engineered for high SST2 receptor selectivity. As a high-affinity SST2 receptor agonist, it suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion while inhibiting serotonin and neuroendocrine peptide hormone release. Supplied as a Research Grade (RUO) lyophilized powder with ≥98% HPLC purity from UPOR Biotech.
Request a QuoteProduct Overview
Lanreotide acetate (CAS 127984-74-1, C₅₄H₆₉N₁₁O₁₀S₂·C₂H₄O₂, MW 1156.38 g/mol) is the acetate salt of lanreotide (BIM 23014), a synthetic cyclic octapeptide analogue of somatostatin-14 engineered for prolonged action and high selectivity toward the somatostatin receptor subtype 2 (SST2). The free base (CAS 108736-35-2) has the formula C₅₄H₆₉N₁₁O₁₀S₂ and a molecular weight of 1096.32 g/mol; the acetate salt adds one equivalent of acetic acid (C₂H₄O₂). As a high-affinity SST2 receptor agonist, lanreotide suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion — the core axis dysregulated in acromegaly — and inhibits the release of serotonin and other neuroendocrine peptide hormones implicated in carcinoid syndrome. UPOR Biotech supplies lanreotide acetate as a white to off-white lyophilized powder with ≥98.0% HPLC purity and a peptide content of ≥85%, suitable for receptor binding, cell-signaling, and secretion assays.
As a specialist supplier of research peptides, UPOR Biotech provides lanreotide acetate for endocrinology, acromegaly, and neuroendocrine tumor (NET) research programs. Lanreotide acetate is the active principle of the reference product Somatuline (lanreotide autogel), a long-acting SST2 agonist indicated clinically for acromegaly and gastroenteropancreatic neuroendocrine tumors — a context provided here for reference only. Research Use Only (RUO) — not for human diagnostic or therapeutic use. Certifications include ISO 9001, cGMP, and FDA facility registration. Packaging is available in 1 mg, 5 mg, 10 mg, and 50 mg vials with full analytical documentation.
Lanreotide Acetate vs Lanreotide (Free Base) — Acetate Salt Lyophilized Form
The key distinction between lanreotide acetate and lanreotide free base is the counter-ion and physical form, not the pharmacology. The acetate salt is the standard lyophilized peptide form, providing enhanced aqueous solubility and improved long-term stability versus the free base — critical for a cyclic disulfide-linked octapeptide. Both forms share the identical amino acid sequence (D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂, disulfide Cys²–Cys⁷) and the same SST2 agonist pharmacology: suppression of GH/IGF-1 and neuroendocrine hormone secretion. The acetate salt differs only in the added acetic acid molecule — raising the molecular weight from 1096.32 g/mol (free base) to 1156.38 g/mol (monoacetate). For researchers, the acetate salt’s superior solubility and shelf stability make it the preferred form for reconstitution and reproducible assay work.
Technical Specifications
| Property | Specification |
|---|---|
| Product Name | Lanreotide Acetate (Somatostatin Analog, Acetate Salt) |
| Synonyms | Lanreotide Acetate; BIM 23014 |
| CAS Number | 127984-74-1 (acetate) / 108736-35-2 (free base) |
| Molecular Formula | C₅₄H₆₉N₁₁O₁₀S₂·C₂H₄O₂ (monoacetate) |
| Molecular Weight | 1156.38 g/mol (acetate) / 1096.32 g/mol (free base) |
| Salt Form | Acetate |
| Peptide Class | Cyclic octapeptide somatostatin analogue |
| Amino Acid Sequence | D-β-Nal¹–Cys²–Tyr³–D-Trp⁴–Lys⁵–Val⁶–Cys⁷–Thr⁸–NH₂ (disulfide Cys²–Cys⁷) |
| Mechanism | High-affinity SST2 (somatostatin receptor subtype 2) agonist |
| Purity (HPLC) | ≥98.0% |
| Peptide Content | ≥85% |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water (reconstitution), DMSO, and aqueous buffers |
| Endotoxin | ≤1.0 EU/mg |
| Water Content | ≤5.0% |
| Counter-ion | Acetate |
| pH | 5.0 – 7.0 (1 mg/mL aqueous solution) |
| Heavy Metals | ≤10 ppm |
| Storage | -20°C, desiccated, protected from light |
| Grade | Research Grade (RUO) |
| Applications | Acromegaly, neuroendocrine tumor (NET), somatostatin receptor pharmacology, GH/IGF-1 research |
| Certifications | ISO 9001, cGMP, FDA facility registration |
| Packaging | 1 mg / 5 mg / 10 mg / 50 mg vials (lyophilized) |
| Shelf Life | 2 years at -20°C |
| Reference Context | Active principle of Somatuline (lanreotide autogel) — reference only |
| Related Analogues | Octreotide; pasireotide; somatostatin-14 |
| Disclaimer | Research Use Only (RUO) — not for human diagnostic or therapeutic use |
Key Benefits — Lanreotide Acetate
SST2-Selective Somatostatin Agonism
Lanreotide acetate binds the somatostatin receptor subtype 2 (SST2) with high affinity, recapitulating the inhibitory signaling of native somatostatin-14. This SST2 selectivity — engineered into the cyclic octapeptide sequence — enables targeted investigation of receptor-mediated inhibition of secretion and proliferation.
SST2 SelectiveGH & IGF-1 Suppression
As an SST2 agonist, lanreotide acetate suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion — the central axis of acromegaly pathophysiology — while also inhibiting serotonin and neuroendocrine peptide hormone release relevant to carcinoid syndrome.
GH/IGF-1 SuppressionStable Acetate Salt Lyophilized Form
The acetate salt is the standard lyophilized peptide form, offering enhanced aqueous solubility and improved long-term stability versus the free base. This supports reliable reconstitution and reproducible assay performance for a cyclic disulfide-linked peptide.
Acetate Salt≥98% HPLC Purity Research Peptide
Supplied with ≥98.0% HPLC purity and ≥85% peptide content, lanreotide acetate is manufactured under ISO 9001 and cGMP quality systems with FDA facility registration — delivering a high-integrity tool compound for receptor pharmacology and endocrine research.
≥98% HPLCApplications
Acromegaly & Growth Hormone Research
Lanreotide acetate models SST2-mediated suppression of growth hormone (GH) and IGF-1 hypersecretion, supporting mechanistic studies of the somatostatin-GH axis underlying acromegaly.
Neuroendocrine Tumor (NET) Studies
Used to investigate SST2 agonist inhibition of neuroendocrine tumor cell secretion and growth, with the reference context of Somatuline (lanreotide autogel) for comparative pharmacology.
Somatostatin Receptor Pharmacology
A reference agonist for SST2 receptor binding, selectivity profiling across SSTR subtypes, and downstream signaling (cAMP, Gi/o) assays in receptor pharmacology.
Carcinoid Syndrome & Hormone Secretion Research
Probes inhibition of serotonin and neuroendocrine peptide hormone release, modeling the biochemical hallmarks of carcinoid syndrome in secretion studies.
Cancer Cell Proliferation Studies
Supports investigation of SST2-mediated antiproliferative signaling in somatostatin-receptor-expressing cancer cell lines and proliferation assays.
Peptide Reference Standard & Assay Development
High-purity lyophilized material for HPLC and mass spectrometry reference standards, method development, and quantitative assay calibration.
Frequently Asked Questions
Lanreotide acetate (BIM 23014, CAS 127984-74-1) is the acetate salt of lanreotide, a synthetic cyclic octapeptide analogue of somatostatin-14 engineered for high selectivity toward the somatostatin receptor subtype 2 (SST2). As a high-affinity SST2 receptor agonist, it suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion, inhibits serotonin and neuroendocrine peptide hormone release, and slows cell proliferation. Supplied as a lyophilized powder for research use only.
Lanreotide acetate is the acetate salt form of lanreotide (free base CAS 108736-35-2). The acetate counter-ion yields the standard lyophilized peptide form with enhanced aqueous solubility and improved long-term stability versus the free base. Both share the identical amino acid sequence and SST2 agonist pharmacology — differing only in counter-ion, molecular formula (C₅₄H₆₉N₁₁O₁₀S₂·C₂H₄O₂), and molecular weight (1156.38 g/mol versus 1096.32 g/mol for the free base).
Lanreotide acetate is used in acromegaly and growth hormone research, neuroendocrine tumor (NET) studies, somatostatin receptor subtype 2 (SST2) pharmacology, carcinoid syndrome and hormone secretion research, cancer cell proliferation studies, and as a peptide reference standard for assay development. It is a widely cited tool compound for probing SST2-mediated inhibition of GH/IGF-1 and neuroendocrine hormone secretion.
Store lanreotide acetate lyophilized powder at -20°C in a desiccated, light-protected environment. For reconstitution, dissolve in sterile water, DMSO, or aqueous buffer to the desired working concentration, then aliquot to avoid repeated freeze-thaw cycles. Reconstituted solutions should be used promptly and stored at -20°C for short-term use. The cyclic disulfide (Cys²–Cys⁷) remains stable under these recommended conditions.
Every shipment includes a Certificate of Analysis (COA) with HPLC purity (≥98.0%), peptide content (≥85%), endotoxin (≤1.0 EU/mg), water content, and heavy metals; MSDS; HPLC chromatogram; mass spectrometry (MS) confirmation of molecular weight; and lot traceability. UPOR Biotech operates under ISO 9001 and cGMP quality systems with FDA facility registration. All product is supplied as Research Grade (RUO) — not for human diagnostic or therapeutic use.